兄弟科技(002562) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥689,370,526.73, representing a 50.48% increase compared to ¥458,113,413.25 in the same period last year[9] - Net profit attributable to shareholders decreased by 43.95% to ¥11,124,807.00 from ¥19,849,624.40 year-on-year[9] - The net profit after deducting non-recurring gains and losses fell by 48.77% to ¥9,851,726.82 compared to ¥19,231,391.57 in the previous year[9] - Basic and diluted earnings per share decreased by 54.55% to ¥0.01 from ¥0.022 year-on-year[9] - The company's net profit for the current period is ¥388,429.06, a recovery from a net loss of ¥21,525,124.89 in the previous period[48] - The total comprehensive income for the current period is ¥388,429.06, recovering from a total comprehensive loss of ¥21,525,124.89 in the previous period[48] Cash Flow - The net cash flow from operating activities was negative at -¥74,991,152.46, a 9.42% increase in outflow compared to -¥68,532,959.78 in the same period last year[9] - The total cash inflow from operating activities is ¥527,984,989.70, up from ¥375,406,320.57 in the previous period[51] - The cash flow from investing activities shows a net outflow of ¥41,820,242.13, an improvement from a net outflow of ¥739,395,696.34 in the previous period[51] - The cash inflow from financing activities totaled ¥120,000,000.00, up from ¥93,735,600.00 year-over-year[55] - The net cash flow from financing activities was -¥20,395,050.93, a decrease from an inflow of ¥28,399,224.32 in the same quarter last year[55] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,404,045,046.43, a slight increase of 0.85% from ¥5,358,440,754.77 at the end of the previous year[9] - The total liabilities of the company were CNY 2,376,652,875.00, up from CNY 2,331,756,313.34, marking an increase of approximately 1.93%[35] - The company's equity attributable to shareholders reached CNY 3,027,392,171.43, a slight increase from CNY 3,026,684,441.43, indicating a growth of about 0.02%[36] Operating Costs and Expenses - Operating costs surged by 96.02% to CNY 610,758,642.72, mainly due to increased sales volume[16] - The total operating costs amounted to CNY 673,322,828.24, up from CNY 424,390,063.36 in the prior period, indicating a rise in costs associated with revenue growth[42] - Management expenses decreased by 37.67% to CNY 45,935,107.24, attributed to the previous period's project debugging costs[16] - Research and development expenses for the quarter were CNY 15,801,279.23, compared to CNY 14,438,462.98 in the prior year, indicating continued investment in innovation[42] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,713[12] - Net assets attributable to shareholders were ¥3,027,392,171.43, showing a marginal increase of 0.02% from ¥3,026,684,441.43 at the end of the previous year[9] Investment Activities - The company plans to invest CNY 2.5 billion in an international pharmaceutical industry base, with CNY 1.5 billion allocated for fixed assets[17] - The company has committed CNY 415 million to wealth management products, with a remaining balance of CNY 395 million[25] - The company did not undergo an audit for the first quarter report[57] - The company did not apply the new leasing standards for the first quarter of 2021[56] Miscellaneous - The company reported non-recurring gains of ¥1,273,080.18 for the period, primarily from government subsidies and asset disposals[10] - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[26][27] - The impact of exchange rate changes on cash and cash equivalents was -¥460,578.96, compared to an increase of ¥325,754.49 in the previous year[55]